Loading clinical trials...
Loading clinical trials...
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Phase I/II Study of Carfilzomib, Ruxolitinib, and Low Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma
Conditions
Interventions
Carfilzomib
Ruxolitinib
+1 more
Locations
2
United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Start Date
January 3, 2019
Primary Completion Date
November 7, 2022
Completion Date
February 21, 2024
Last Updated
January 13, 2025
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Wake Forest University Health Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions